H. Lundbeck A/S (Lundbeck) reports first half revenue of DKK 6,829 million, excluding Lexapro® in the US, an increase of 1% compared to the first half of 2011. EBITDA and EBIT, excluding restructuring costs were DKK 1,742 million and DKK 1,264 million respectively, corresponding to an EBITDA margin of 24% and an EBIT margin of 17%.

Luqa Pharmaceuticals announced today that it has entered into an exclusive agreement with Stratpharma AG of Switzerland to promote, sell, and distribute Strataderm®, in the People's Republic of China.

Affinium Pharmaceuticals announced that full recruitment has been achieved in its multi-center Phase 2 clinical trial evaluating oral AFN-1252 in acute bacterial skin & skin structure infections ("ABSSSI").

Boehringer Ingelheim has announced an agreement with Servier and its partner XOMA Corporation (Nasdaq: XOMA) to transfer XOMA's technology and process for the commercial manufacture of gevokizumab, XOMA's novel interleukin 1-beta (IL-1β) allosteric modulating antibody.

The Bristol-Myers Squibb Foundation announced $1.6 million in grants to four health care institutions in India that will help improve diabetes education, prevention and care and increase health care worker capacity in rural and tribal areas and among the urban poor.

Novartis and the University of Pennsylvania (Penn) announced today an exclusive global collaboration to research, develop and commercialize targeted chimeric antigen receptor (CAR) immunotherapies for the treatment of cancers.

In the second quarter of 2012, Sanofi generated net sales of €8,870 million, up 6.2% on a reported basis. Exchange rate movements had a positive effect of 5.8 percentage points reflecting the appreciation of the U.S. dollar and, to a lesser extent, the appreciation of the Japanese Yen and Chinese Yuan against the Euro.